The prevalence of liver cancer is constantly rising, with increasing incidence and mortality in
Europe and the USA in recent decades. Among the different subtypes of liver cancers …

Introduction Hepatocellular carcinoma (HCC) represents the sixth most commonly
diagnosed malignancy worldwide, accounting for millions of deaths annually. Despite …

Lenvatinib is a multikinase inhibitor approved as a first‐line therapy for advanced
hepatocellular carcinoma (HCC). However, the development of drug resistance is common …

Cases of hepatocellular carcinoma (HCC) are rapidly rising. This is particularly the case in
the Western world, as a result of increasing rates of chronic liver disease, secondary to …

Simple Summary Hepatocellular carcinoma accounts for around 75% of all liver cancers,
and represents the fourth most common cause of cancer-related deaths worldwide …

Hepatocellular carcinoma (HCC) is characterized by low resection and high postoperative
recurrence rates, and conventional treatment strategies have failed to meet clinical needs …

Advanced osteosarcoma (OSA) is highly aggressive and can lead to distant metastasis or
recurrence. Here, a novel small-molecule inhibitor/antagonist of DNA methyltransferase 1 …

Background and aims Liver cancer is a detrimental complication in patients with chronic viral
hepatitis and alcoholic or nonalcoholic fatty liver disease (NAFLD). However, metabolic risk …

Liver cancer, a chronic non-communicable disease, represents a serious public health
problem. Long-term trends in the burden of liver cancer disease are heterogeneous across …

Simple Summary At present, research on tertiary lymphoid structures (TLSs) in
hepatocellular carcinoma (HCC) has been limited to the prognostic impact. Our manuscript …